The Washington Supreme Court issued a decision in Erickson vs. Monsanto which impacts several legal issues across cases involving allegations of exposure to polychlorinated biphenyls at the Sky Valley Education Center, Bayer (BAYRY) announced. “The company disagrees with the Supreme Court’s decision to reverse the Court of Appeals in Erickson and deny Monsanto’s cross-petition regarding the availability of punitive damages. In particular, the company believes that the Court’s choice-of-law analyses underlying its rulings on punitive damages and the statute of repose are wrong and contrary to the U.S. Constitution because the rulings unlawfully discriminate against out of state companies doing business in Washington. Three dissenting justices found in favor of the company on its entitlement to a statue of repose defense under Washington law, writing: ‘…courts are not supposed to start their analysis with policy preferences when there’s a state statute right on point.’ The company is considering its legal options,” Bayer stated.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer’s New Study on Mirena: A Potential Game-Changer for Endometrial Hyperplasia Treatment
- Bayer’s Rivaroxaban Study: A New Chapter in Pediatric Heart Care
- Bayer’s New Study on Darolutamide: A Potential Game-Changer for Prostate Cancer Treatment?
- Bayer’s Phase I Study on Advanced Cancer Treatment Shows Promise
- Bayer AG’s Exploratory Study on Sepsis and DIC: A Potential Game Changer in Healthcare
